Sie sind auf Seite 1von 6

InnoCore Pharmaceuticals is a b

iopharmaceutical
drug delivery company specialized in the
development of long acting and minimally
invasive injectable drug d
elivery products
for the treatment of chronic diseases.
InnoCores drug delivery technologies
are currently applied in co-development
programs to create proprietary p
roducts
for the following disease areas and
administration routes:
Diseases
Prostate cancer
Schizophrenia
Pain management
Atherosclerosis
Macular degeneration
Cardiac repair
Kidney disease
Osteoarthritis
Melanoma
Administration routes
Subcutaneous
Intramuscular
intraocular
intra articular
intrathecal
intra arterial

Partnering opportunities
InnoCore is interested in licensing its proprietary technologies and in new partnerships to co-develop injectable drug delivery products for generic drugs and promising
new therapeutic molecules that may benefit from the combination with InnoCores
proprietary drug delivery technologies. Being a small sized organization, we are
flexible in constructing partnership agreements and focused on efficient product
development. Our priority is to build successful long-term partnerships. We believe
that only truly collaborative relationships lead to mutually beneficial partnerships.

InnoCore Pharmaceuticals is based in Groningen. The city of Groningen


is located in the northern part of The Netherlands.
InnoCore Pharmaceuticals
L.J. Zielstraweg 1
NL-9713 GX Groningen
The Netherlands
T
F
E
I

Science delivering
tomorrows medicines
Corporate brochure

+31 (0)50 575 31 00


+31 (0)50 577 3537
info@innocorepharma.com
www.innocorepharma.com

InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company


specialized in the development of long acting and minimally invasive drug
delivery products for the treatment of chronic d
iseases.

InnoCore Pharmaceuticals is a biopharmaceutical drug


delivery company specialized in the development of long

Drug delivery technologies

Proprietary product pipeline

Development in partnership

InnoCore has developed and co-markets various bio


degradable polymeric drug delivery technologies for the
development of long acting and minimally invasive parenteral depot formulations for virtually all drug classes.

InnoCore is co-developing a number of proprietary products based on its drug delivery platforms and
manufacturing technologies. Please visit our website www.innocorepharma.com to view the current status
of our pipeline and for partnering and licensing opportunities. InnoCore is interested in new partnerships to
co-develop injectable drug delivery products for generic drugs or promising new therapeutic molecules that
may benefit from the combination with its proprietary and non-proprietary drug delivery technologies.

It is our mission to serve the pharmaceutical and medical device industry


with advanced drug delivery systems.
We do this in many different ways
but always in collaboration with our
customers.

acting and minimally invasive drug delivery products for

SynBioys biodegradable polymers Proprietary bio

the treatment of chronic diseases.

degradable multi-block co-polymer platform for the controlled release of small molecules, peptides and proteins.

Product

Indication

ICP101 eluting coronary stent

Atherosclerosis

Injectable solid implants Our injectable solid implants

Goserelin, 1 month depot

Prostate cancer

InnoCore Pharmaceuticals is dedicated to the development of drug


delivery products that offer optimal control over the release kinetics and bioactivity of therapeutic agents as to improve pharmacotherapeutic efficacy and reduce side effects. InnoCore partners with
pharmaceutical, biotechnology and medical device companies to
develop and commercialize pharmaceutical depot formulations and
drug eluting medical devices based on its advanced biodegradable
polymeric drug delivery systems.
InnoCores strategy is to capitalize on its proprietary drug d elivery
technologies, manufacturing capabilities and pharmaceutical
development expertise by:
Internal and partnered development of promising drug delivery
technologies;
Licensing of its technologies and providing pharmaceutical
development capabilities and services to third parties to develop
proprietary drug delivery products for a wide range of molecules
and therapeutic indications;
Co-development of promising products based on its drug delivery
platforms.

are used as injectable subcutaneous and ocular depots


for long term drug delivery up to 6 months and are manufactured by low temperature extrusion to preserve the
bioactivity of the encapsulated drug molecule.

Goserelin, 3 months depot

Prostate cancer

Goserelin, 6 months depot

Prostate cancer

InnoCore is dedicated to the creation of tomorrows medicines by


applying proprietary and non-proprietary technologies, its scientific
expertise and development services. InnoCore offers its proprietary
drug delivery technologies for licensing and has entered into a
number of successful partnerships with third parties to co-develop
controlled release formulations. The company has been profitable
since the start.

sphere technology for parenteral depot formulations


with superior injectability and precisely controlled drug
delivery (in collaboration with Nanomi).
Medical device coatings Biodegradable drug eluting

coatings to improve the functionality of medical devices


such as drug eluting stents.
Injectable hydrogels Physically crosslinked injectable

hydrogels for c ontrolled release of proteins and other


drugs (in collaboration with InGell Labs).
Protein stabilization Stabilization of proteins and

b iological macromolecules via encapsulation in inulin


glasses, a natural polysaccharide (GRAS status).

Pre-clinical

Phase I/II

Phase III

Market

Sirolimus eluting coronary stent Atherosclerosis

Science delivering tomorrows medicine

Microspheres InnoCore offers monodisperse micro-

R&D

Pharmaceutical development

Analytical laboratories

Founded in 2003, InnoCore has become an expert center for the development of biodegradable polymeric drug delivery products for the pharma
ceutical, biotech and medical device industry. Core competences and
services include custom polymer synthesis, cGMP polymer manufacturing,
analytical development, pharmaceutical development, process development
and scale-up, phase I/II clinical manufacturing, and regulatory support.
As per 2009 InnoCore opened a new biopharmaceutical R&D facility
equipped with dedicated process equipment for:
extrusion of solid injectable implants
ultrasonic spraycoating of drug eluting stents
small scale microsphere manufacturing
lyophilization.

Analytical techniques for chemical characterization of our


polymers (and depot formulations) include intrinsic viscosity,
GPC, DSC, GC, 1H NMR, FT-IR, RP-HPLC and Karl Fisher. Further
analytical techniques include dissolution testing, Coulter Counter particle size analysis and scanning electron microscopy.
Analytical biochemistry and immunochemistry involves
identification and quantification of proteins, peptides and
other biomolecules using techniques including RP-HPLC, UPLC,
SEC-HPLC, UV/IR spectrometry, circular dichroism, FT-IR, mass
spectrometry, BCA, ELISA and SDS-PAGE.

Furthermore InnoCore has the disposal of cleanrooms (ISO class 6 and 8) for
manufacturing of animal trial material as well as climate chambers for ICH
stability studies.

Improvement through collaboration

Besides out-licensing of our proprietary drug delivery technologies, we


offer fully integrated pharmaceutical
development of drug delivery products.
This includes formulation development, stability testing, synthesis and
scale-up of custommade polymers,
process development and cGMP
manufacturing of clinical trial material.
Whether you are in the pharmaceutical, biotech or medical device industry,
working on generic products or in need
of a novel drug delivery system to meet
the formulation challenges of your new
biological therapeutic, we can help you
to achieve your strategic goals faster.

cGMP manufacturing for clinical studies


cGMP manufacturing of SynBiosys polymers for clinical and
commercial purposes is outsourced to a CMO under a supply
agreement. InnoCore is currently integrating its microsphere
and implant manufacturing processes into cGMP facilities for
aseptic fill and finish of parenteral products. As per 2012 cGMP
manufacturing of parenteral depot formulations will be offered
to facilitate phase I/II clinical studies following successful
product development.

Service and capabilities

With our in-house polymer synthesis and drug delivery formulation expertise,
we can create sustained release depot formulations for your bioactive compounds
and according to your specifications. Together with our strategic partners, we offer
innovative solutions for formulation and delivery of therapeutic peptides and
biotech-derived drugs, including:
Monodisperse microspheres

InnoCore partners with Nanomi on monodisperse controlled release microsphere


technology. Monodisperse microspheres allow for minimally invasive and less
painful injection through very thin needles (27 Gauge and smaller) and enable new
delivery strategies, such as capillary embolization following intra arterial administration. Moreover, particle related immunoactivation is circumvented due to the
absence of 10 m particles.
The combination of InnoCores SynBiosys polymer platform with Nanomis robust
and scalable Monosphere Technology process, offers an attractive route for
development of parenteral depot formulations with superior injectability for the
systemic or site-specific delivery of even the most challenging biological molecules.
Sugar glass protein stabilization technology

Proteins are typically formulated using buffered aqueous solutions. However,


protein solutions may be unstable and not suitable for further processing into
advanced dosage forms. InnoCore collaborates with the University of Groningen
on stabilization of proteins through lyophilization and spray-drying of proteins in
amorphous sugar matrices.

Proof of concept

Pharmaceutical

Process

studies

development

development

manufacturing

transfer

Feasibility

Product

Process engineering

cGMP batches for

Enabling

assessment

optimization

and scale-up

phase I/II clinical

commercial

studies

manufacturing


Drug delivery technologies
Clinical product development
cGMP Manufacturing

Clinical

Technology

InnoCore Pharmaceuticals is a biopharmaceutical drug


delivery company specialized in the development of long

Drug delivery technologies

Proprietary product pipeline

Development in partnership

InnoCore has developed and co-markets various bio


degradable polymeric drug delivery technologies for the
development of long acting and minimally invasive parenteral depot formulations for virtually all drug classes.

InnoCore is co-developing a number of proprietary products based on its drug delivery platforms and
manufacturing technologies. Please visit our website www.innocorepharma.com to view the current status
of our pipeline and for partnering and licensing opportunities. InnoCore is interested in new partnerships to
co-develop injectable drug delivery products for generic drugs or promising new therapeutic molecules that
may benefit from the combination with its proprietary and non-proprietary drug delivery technologies.

It is our mission to serve the pharmaceutical and medical device industry


with advanced drug delivery systems.
We do this in many different ways
but always in collaboration with our
customers.

acting and minimally invasive drug delivery products for

SynBioys biodegradable polymers Proprietary bio

the treatment of chronic diseases.

degradable multi-block co-polymer platform for the controlled release of small molecules, peptides and proteins.

Product

Indication

ICP101 eluting coronary stent

Atherosclerosis

Injectable solid implants Our injectable solid implants

Goserelin, 1 month depot

Prostate cancer

InnoCore Pharmaceuticals is dedicated to the development of drug


delivery products that offer optimal control over the release kinetics and bioactivity of therapeutic agents as to improve pharmacotherapeutic efficacy and reduce side effects. InnoCore partners with
pharmaceutical, biotechnology and medical device companies to
develop and commercialize pharmaceutical depot formulations and
drug eluting medical devices based on its advanced biodegradable
polymeric drug delivery systems.
InnoCores strategy is to capitalize on its proprietary drug d elivery
technologies, manufacturing capabilities and pharmaceutical
development expertise by:
Internal and partnered development of promising drug delivery
technologies;
Licensing of its technologies and providing pharmaceutical
development capabilities and services to third parties to develop
proprietary drug delivery products for a wide range of molecules
and therapeutic indications;
Co-development of promising products based on its drug delivery
platforms.

are used as injectable subcutaneous and ocular depots


for long term drug delivery up to 6 months and are manufactured by low temperature extrusion to preserve the
bioactivity of the encapsulated drug molecule.

Goserelin, 3 months depot

Prostate cancer

Goserelin, 6 months depot

Prostate cancer

InnoCore is dedicated to the creation of tomorrows medicines by


applying proprietary and non-proprietary technologies, its scientific
expertise and development services. InnoCore offers its proprietary
drug delivery technologies for licensing and has entered into a
number of successful partnerships with third parties to co-develop
controlled release formulations. The company has been profitable
since the start.

sphere technology for parenteral depot formulations


with superior injectability and precisely controlled drug
delivery (in collaboration with Nanomi).
Medical device coatings Biodegradable drug eluting

coatings to improve the functionality of medical devices


such as drug eluting stents.
Injectable hydrogels Physically crosslinked injectable

hydrogels for c ontrolled release of proteins and other


drugs (in collaboration with InGell Labs).
Protein stabilization Stabilization of proteins and

b iological macromolecules via encapsulation in inulin


glasses, a natural polysaccharide (GRAS status).

Pre-clinical

Phase I/II

Phase III

Market

Sirolimus eluting coronary stent Atherosclerosis

Science delivering tomorrows medicine

Microspheres InnoCore offers monodisperse micro-

R&D

Pharmaceutical development

Analytical laboratories

Founded in 2003, InnoCore has become an expert center for the development of biodegradable polymeric drug delivery products for the pharma
ceutical, biotech and medical device industry. Core competences and
services include custom polymer synthesis, cGMP polymer manufacturing,
analytical development, pharmaceutical development, process development
and scale-up, phase I/II clinical manufacturing, and regulatory support.
As per 2009 InnoCore opened a new biopharmaceutical R&D facility
equipped with dedicated process equipment for:
extrusion of solid injectable implants
ultrasonic spraycoating of drug eluting stents
small scale microsphere manufacturing
lyophilization.

Analytical techniques for chemical characterization of our


polymers (and depot formulations) include intrinsic viscosity,
GPC, DSC, GC, 1H NMR, FT-IR, RP-HPLC and Karl Fisher. Further
analytical techniques include dissolution testing, Coulter Counter particle size analysis and scanning electron microscopy.
Analytical biochemistry and immunochemistry involves
identification and quantification of proteins, peptides and
other biomolecules using techniques including RP-HPLC, UPLC,
SEC-HPLC, UV/IR spectrometry, circular dichroism, FT-IR, mass
spectrometry, BCA, ELISA and SDS-PAGE.

Furthermore InnoCore has the disposal of cleanrooms (ISO class 6 and 8) for
manufacturing of animal trial material as well as climate chambers for ICH
stability studies.

Improvement through collaboration

Besides out-licensing of our proprietary drug delivery technologies, we


offer fully integrated pharmaceutical
development of drug delivery products.
This includes formulation development, stability testing, synthesis and
scale-up of custommade polymers,
process development and cGMP
manufacturing of clinical trial material.
Whether you are in the pharmaceutical, biotech or medical device industry,
working on generic products or in need
of a novel drug delivery system to meet
the formulation challenges of your new
biological therapeutic, we can help you
to achieve your strategic goals faster.

cGMP manufacturing for clinical studies


cGMP manufacturing of SynBiosys polymers for clinical and
commercial purposes is outsourced to a CMO under a supply
agreement. InnoCore is currently integrating its microsphere
and implant manufacturing processes into cGMP facilities for
aseptic fill and finish of parenteral products. As per 2012 cGMP
manufacturing of parenteral depot formulations will be offered
to facilitate phase I/II clinical studies following successful
product development.

Service and capabilities

With our in-house polymer synthesis and drug delivery formulation expertise,
we can create sustained release depot formulations for your bioactive compounds
and according to your specifications. Together with our strategic partners, we offer
innovative solutions for formulation and delivery of therapeutic peptides and
biotech-derived drugs, including:
Monodisperse microspheres

InnoCore partners with Nanomi on monodisperse controlled release microsphere


technology. Monodisperse microspheres allow for minimally invasive and less
painful injection through very thin needles (27 Gauge and smaller) and enable new
delivery strategies, such as capillary embolization following intra arterial administration. Moreover, particle related immunoactivation is circumvented due to the
absence of 10 m particles.
The combination of InnoCores SynBiosys polymer platform with Nanomis robust
and scalable Monosphere Technology process, offers an attractive route for
development of parenteral depot formulations with superior injectability for the
systemic or site-specific delivery of even the most challenging biological molecules.
Sugar glass protein stabilization technology

Proteins are typically formulated using buffered aqueous solutions. However,


protein solutions may be unstable and not suitable for further processing into
advanced dosage forms. InnoCore collaborates with the University of Groningen
on stabilization of proteins through lyophilization and spray-drying of proteins in
amorphous sugar matrices.

Proof of concept

Pharmaceutical

Process

studies

development

development

manufacturing

transfer

Feasibility

Product

Process engineering

cGMP batches for

Enabling

assessment

optimization

and scale-up

phase I/II clinical

commercial

studies

manufacturing


Drug delivery technologies
Clinical product development
cGMP Manufacturing

Clinical

Technology

InnoCore Pharmaceuticals is a privately owned Dutch


biopharmaceutical drug delivery company specialized in

Proprietary drug delivery technologies

Proprietary product pipeline

Development in partnership

InnoCore has developed and comarkets various propri


etary drug delivery technologies for the development
of long acting and minimally invasive parenteral depot
formulations for virtually all drug classes and therapeutic
indications.

InnoCore is co-developing a proprietary product pipeline based on its proprietary drug delivery
platforms and manufacturing technologies.
Please visit our website www.innocorepharma.com to view the current status of our pipeline and
partnering and licensing opportunities. InnoCore is interested in new product opportunities around
combinations of generic drugs or NCEs with our proprietary drug delivery technologies.

It is InnoCores mission to serve the


pharnaceutical and medical device
industry with advanced drug delivery
systems. We do this in many different
ways but always in collaboration with
our customers.

SynBioys

Product

Indication

Proprietary biodegradable multi-block co-polymer


platform for the controlled release of small molecules,
peptides and proteins.

Combo sirolimus eluting stent

Atherosclerosis

Drug eluting stent

Atherosclerosis

Goserelin, 1 month

Prostate cancer

the development of long-acting and minimally invasive


injectable depot formulations and drug eluting medical
devices for precise delivery of small molecules, peptides
and protein therapeutics.

Delivering Tomorrows Medicine


InnoCore Pharmaceuticals partners with pharmaceutical, biotechnol
ogy and medical device companies to develop and commercialize
pharmaceutical products and combination products based on its
proprietary and enabling drug delivery technologies. InnoCore has
multiple on-going development programs from feasibility to clinical
evaluation of which the majority is performed in close collaboration
with its partners.
InnoCore Pharmaceuticals strategy is to capitalize on the wealth of
opportunities afforded by our proprietary controlled reelase tech
nologies in three ways:
To internally develop promising products based on our technolo
gies
To partner some of our product opportunities with development
and/or commercialization partners at appropriate stages along the
development timelines;
To make our technologies, along with our pre-clinical and clinical
development expertise available to partners with the desire to
develop proprietary extended or controlled release formulations
of a wide range of molecules.
InnoCore Pharmaceuticals offers its drug delivery technologies for
licensing to third parties on a product-to-product basis. The com

Goserelin, 3 months

Prostate cancer

Biodegradable solid implants

Goserelin, 6 months

Prostate cancer

Our injectable biodegradable subcutaneous and ocular


implants provide long-term drug delivery for up to 6
months and are prepared by low temperature extrusion to
preserve the integrity and bioactivity of the active agent.

Leuprolide, 1 month

Prostate cancer

Leuprolide, 3 months

Prostate cancer

Microspheres

InnoCore offers microsphere processing and formulation


technology to develop parenteral depot formulations with
improved syringebility for minimally invasive parenteral
delivery (in collaboration with Nanomi).
InGell thermoresponsive gels

Physically crosslinked injectable hydrogels for controlled


release of proteins and other drugs (in collaboration with
InGell Labs)
Protein stabilization

Stabilization of labile proteins and biological macromol


ecules via encapsulation in inulin glasses, a naturally

R&D

Pre-clinical

Phase I

Phase II

Market

Besides out-licensing of our propri


etary drug delivery technologies, we
offer fully integrated pharmaceutical
development of drug delivery products.
This includes formulation develop
ment, stability testing, synthesis and
scale-up of custommade polymers,
process developmentand cGMP manu
facturing of clinical trial material.

Pharmaceutical (contract) development

Analytical laboratory

Founded in 2003, InnoCore has become an expert center for the develop
ment of biodegradable polymeric drug delivery products for the pharma
ceutical, biotech and medical device industry. Core competences and
services include custom polymer synthesis, cGMP polymer manufacturing,
pharmaceutical development, analytical method development, process
development and scale-up and cGMP manufacturing of clinical supplies
As per May 2009 InnoCore opened a dedicated biopharmaceutical R&D
facility. This drug delivery R&D centre comprises amongst others
lyophilization equipment
extrusion line for solid injectable implants,
ultrasonic spray coating equipment for manufacturing of drug eluting
stents
small scale microsphere manufacturing processes.
Cleanrooms (ISO class 6 and 8 ) for manufacturing of animal trial material.
-Climate chambers for ICH stability studies

Analytical techniques for chemical characterization of our poly


mers (and depot formulations) include intrinsic viscosity, GPC,
DSC, GC, 1H NMR, FT-IR, RP-HPLC, Karl Fisher. Further analytical
equipment to characterize drug delivery products include disso
lution testing equipment, Coulter Counter particle size analysis
Analytical biochemistry and immunochemistry involves iden
tification and quantification of proteins, peptides and other
biomolecules using techniques including RP-HPLC/ UPLC, SECHPLC, IEC-HPLC), UV/IR spectrometry, circular dichroism (CD),
Fourier-transform infrared spectroscopy (FT-IR), mass spec
trometry, BCA, ELISA and SDS-PAGE.

Whether you are in the pharmaceuti


cal, biotech or medical device industry,
working on generic products or in need
of a novel drug delivery system to meet
the formulation challenges of your new
biological therapeutic, we can help you
to achieve your strategic goals faster.

cGMP manufacturing of clinical supplies

Product and capabilities

SynBiosys batches for clinical and commercial purposes are


manufactuerd under a supply agreement under cGMP condi
tions. InnoCore is currently integrating its microsphere and im
plant manufacturing processes in cGMP manufacturing facilities
for aseptic fill and finish and lyophilization of parenteral drug
delivery products. With this service InnoCore can provide its

Improvement through collaboration


With our in-house polymer synthesis and drug delivery formulation expertise, we
can create sustained release depot formulations for your bioactive compounds
and according to your specifications. Together with our strategic partners, we offer
innovative solutions for formulation and delivery of therapeutic peptides and
biotech-derived drugs, including:
Monodisperse microspheres

InnoCore partners with Nanomi on monodisperse controlled release microsphere


technology. Monodisperse microspheres allow for minimally invasive and less
painful injection through very thin needles (27 Gauge and smaller) and enable new
delivery strategies, such as capillary embolization following intra-arterial admin
istration. Moreover, particle related immunoactivation is circumvented due to the
absence of < 10 m particles.
The combination of InnoCores SynBiosys polymer platform with Nanomis robust
and scalable microsieve emulsification based Monosphere process technology, of
fers an attractive route for development of parenteral depot formulations for the
systemic or site-specific delivery of even the most challenging biological molecules.
Sugar glass protein stabilization technology

Proteins are typically formulated using buffered aqueous solutions. However,


protein solutions may be unstable and not suitable for further processing into
advanced dosage forms. InnoCore collaborates with the University of Groningen on
stable dry powder forms of therapeutic proteins through lyophilization and spraydrying of proteins in amorphous sugar matrices.

Feasibility

Product

License

Clinical

Commercial

optimization

agreement

manufacturing

manufacturing

Determine best

Determine best

Partnership based

Scale-up and

Satisfy market

fit technology

fit technology

business model

clinical supply

demands

Technology solutions
Clinical product development
cGMP Manufacturing

InnoCore Pharmaceuticals is a privately owned Dutch


biopharmaceutical drug delivery company specialized in
the development of long acting injectable drug d
elivery
products and drug eluting medical devices for the
treatment of chronic diseases.

Co-development projects
InnoCore Pharmaceuticals proprietary
drug delivery technologies are used for
proprietary products in the following
areas technologies:
Diseases
Prostate cancer
Schizophrenia
Pain management
Atherosclerosis
Macular degeneration
Cardiac repair
Kidney disease
Osteoarthritis
Melanoma

InnoCore Pharmaceuticals is located at the Zernike Science Park in Groningen.


The city of Groningen is in the northern part of The Netherlands.

Administration routes
Subcutaneous
Intramuscular
intraocular
intra-articular
intrathecal
intra-arterial

InnoCore Pharmaceuticals
Zernike Park 6 - 8
NL-9747 AN Groningen
The Netherlands
T
F
E
I
I

Delivering tomorrows medicine


Corporate brochure

+31 (0)50 573 0819


+31 (0)50 577 3537
info@innocorepharma.com
www.innocorepharma.com
www.innocore.nl

InnoCore offers special formulation and manufacturing


expertise in thefollowing areas:
Protein and peptide formulations
Microspheres
InGell thermoresponsive gels
Protein stabilisation

freeze-drying/spray-drying
Solid injectable implants
Drug eluting stent coatings

InnoCore Pharmaceuticals is a privately owned Dutch biopharmaceutical


drug delivery company specialized in the development of long acting and
minimally invasive injectable drug delivery products and drug eluting
medical devices for the treatment of chronic diseases.

InnoCore Pharmaceuticals is a b
iopharmaceutical
drug delivery company specialized in the
development of long acting and minimally
invasive injectable drug d
elivery products
for the treatment of chronic diseases.
InnoCores drug delivery technologies
are currently applied in co-development
programs to create proprietary p
roducts
for the following disease areas and
administration routes:
Diseases
Prostate cancer
Schizophrenia
Pain management
Atherosclerosis
Macular degeneration
Cardiac repair
Kidney disease
Osteoarthritis
Melanoma
Administration routes
Subcutaneous
Intramuscular
intraocular
intra articular
intrathecal
intra arterial

Partnering opportunities
InnoCore is interested in licensing its proprietary technologies and in new partnerships to co-develop injectable drug delivery products for generic drugs and promising
new therapeutic molecules that may benefit from the combination with InnoCores
proprietary drug delivery technologies. Being a small sized organization, we are
flexible in constructing partnership agreements and focused on efficient product
development. Our priority is to build successful long-term partnerships. We believe
that only truly collaborative relationships lead to mutually beneficial partnerships.

InnoCore Pharmaceuticals is based in Groningen. The city of Groningen


is located in the northern part of The Netherlands.
InnoCore Pharmaceuticals
L.J. Zielstraweg 1
NL-9713 GX Groningen
The Netherlands
T
F
E
I

Science delivering
tomorrows medicines
Corporate brochure

+31 (0)50 575 31 00


+31 (0)50 577 3537
info@innocorepharma.com
www.innocorepharma.com

InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company


specialized in the development of long acting and minimally invasive drug
delivery products for the treatment of chronic d
iseases.